/EVMN
EVMN Stock - Evommune, Inc.
Healthcare|BiotechnologyNYSE
$18.25+21.59%
+$3.24 (+21.59%) • Dec 19
70
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.37
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.80
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+115.5%upside
Target: $39.33
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for EVMN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$18.07 – $18.43
TARGET (TP)$39.33
STOP LOSS$16.79
RISK/REWARD1:14.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.00
52W High$24.03
52W Low$13.88
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 |
|---|---|---|
| Revenue | $7.00M | $5.00M |
| Gross Profit | $5.71M | $4.00M |
| Gross Margin | 81.6% | 80.0% |
| Operating Income | $-70,013,000 | $-37,850,000 |
| Net Income | $-66,808,000 | $-34,053,000 |
| Net Margin | -954.4% | -681.1% |
| EPS | $-2.27 | $-1.13 |
Company Overview
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products includes EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish0 Neutral/Bearish
Price Targets
$39
Average Target
↑ 115.5% Upside
Now
$36
Low
$39
Average
$42
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 1st 2025 | Leerink Partners | Initiation | Outperform | $42 |
| December 1st 2025 | Morgan Stanley | Initiation | Overweight | $36 |
| December 1st 2025 | William Blair | Initiation | Outperform | - |
| December 1st 2025 | Evercore ISI | Initiation | Outperform | $40 |
| December 1st 2025 | Cantor Fitzgerald | Initiation | Overweight | - |
Earnings History & Surprises
EVMNBeat Rate
0%
Last 1 quarters
Avg Surprise
-623.8%
EPS vs Estimate
Beats / Misses
0/1
Last 12 quarters
Latest EPS
$-8.07
Q4 2025
EPS Surprise History
Q4 25
-623.8%
$-8.07vs$-1.11
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 12, 2026 | $-1.04 | — | — | — |
Q4 2025 | Dec 11, 2025 | $-1.11 | $-8.07 | -623.8% | ✗ MISS |
Latest News
William Blair Initiates Coverage On Evommune with Outperform Rating
📈 PositiveBenzinga•Dec 1, 2025, 02:49 PM
Cantor Fitzgerald Initiates Coverage On Evommune with Overweight Rating
📈 PositiveBenzinga•Dec 1, 2025, 02:06 PM
Morgan Stanley Initiates Coverage On Evommune with Overweight Rating, Announces Price Target of $36
📈 PositiveBenzinga•Dec 1, 2025, 01:07 PM
Leerink Partners Initiates Coverage On Evommune with Outperform Rating, Announces Price Target of $42
📈 PositiveBenzinga•Dec 1, 2025, 12:30 PM
Evercore ISI Group Initiates Coverage On Evommune with Outperform Rating, Announces Price Target of $40
📈 PositiveBenzinga•Dec 1, 2025, 12:25 PM
Reported Earlier, Evommune Announces Pricing Of Initial Public Offering Of 9.38M Shares At $16.00 Per Share, Expected To Raise $150M
📈 PositiveBenzinga•Nov 6, 2025, 08:28 AM
Frequently Asked Questions about EVMN
What is EVMN's current stock price?
Evommune, Inc. (EVMN) is currently trading at $18.25 per share. The stock has moved +21.59% today.
What is the analyst price target for EVMN?
The average analyst price target for EVMN is $39.33, based on 1 analyst.
What sector is Evommune, Inc. in?
Evommune, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NYSE exchange.
What is EVMN's market cap?
Evommune, Inc. has a market capitalization of $0.23 billion, making it a small-cap company.
Does EVMN pay dividends?
No, Evommune, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARTV
Artiva Biotherapeutics, Inc.
$4.74
Mkt Cap: $0.1B
CDXS
Codexis, Inc.
$1.66
Mkt Cap: $0.1B
CLYM
Climb Bio, Inc.
$4.28
Mkt Cap: $0.3B
EYPT
EyePoint Pharmaceuticals, Inc.
$17.43
Mkt Cap: $1.2B
FTRE
Fortrea Holdings Inc.
$17.74
Mkt Cap: $1.6B
GLPG
Galapagos N.V.
$32.36
Mkt Cap: $2.1B
KPTI
Karyopharm Therapeutics Inc.
$6.94
Mkt Cap: $0.1B
LGND
Ligand Pharmaceuticals Incorporated
$200.33
Mkt Cap: $3.9B
OABI
OmniAb, Inc.
$2.09
Mkt Cap: $0.2B
ZYME
Zymeworks Inc.
$27.23
Mkt Cap: $2.0B
Explore stocks similar to EVMN for comparison